Frederick J Raal1, Barbara Sjouke2, G Kees Hovingh3, Barton F Isaac4. 1. Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: frederick.raal@wits.ac.za. 2. Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, PO Box 22660, 1100 DD Amsterdam, Netherlands. Electronic address: b.sjouke@amc.uva.nl. 3. Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1100 DD Amsterdam, Netherlands. Electronic address: g.k.hovingh@amc.uva.nl. 4. Medical Affairs, Sanofi Genzyme, 500 Kendall Street, Cambridge, MA 02142, USA. Electronic address: Barton.isaac@sanofi.com.
Abstract
AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare disorder usually caused by mutations in both alleles of the low-density lipoprotein receptor gene (LDLR). Premature death, often before the age of 20 years, was a common fate for patients with HoFH prior to the introduction of statins in 1990 and the use of lipoprotein apheresis. Consequently, HoFH has been widely considered a condition exclusive to a population comprising very young patients with extremely high LDL cholesterol (LDL-C) levels. However, recent epidemiologic and genetic studies have shown that the HoFH patient population is far more diverse in terms of age, LDL-C levels, and genetic aetiology than previously realised. We set out to investigate the clinical characteristics regarding age and LDL-C ranges of patients with HoFH. METHODS AND RESULTS: We analysed the data from 3 recent international studies comprising a total of 167 HoFH patients. The age of the patients ranged from 1 to 75 years, and a large proportion of the patients, both treated and untreated, exhibited LDL-C levels well below the recommended clinical diagnostic threshold for HoFH. LDL-C levels ranged from 4.4 mmol/L to 27.2 mmol/L (170-1052 mg/dL) for untreated patients, and from 2.6 mmol/L to 20.3 mmol/L (101-785 mg/dL) for treated patients. When patients were stratified according to LDLR functionality, a similarly wide range of age and LDL-C values was observed regardless of LDLR mutation status. CONCLUSION: These results demonstrate that HoFH is not restricted to very young patients or those with extremely high LDL-C levels.
RCT Entities:
AIMS: Homozygous familial hypercholesterolaemia (HoFH) is a rare disorder usually caused by mutations in both alleles of the low-density lipoprotein receptor gene (LDLR). Premature death, often before the age of 20 years, was a common fate for patients with HoFH prior to the introduction of statins in 1990 and the use of lipoprotein apheresis. Consequently, HoFH has been widely considered a condition exclusive to a population comprising very young patients with extremely high LDL cholesterol (LDL-C) levels. However, recent epidemiologic and genetic studies have shown that the HoFH patient population is far more diverse in terms of age, LDL-C levels, and genetic aetiology than previously realised. We set out to investigate the clinical characteristics regarding age and LDL-C ranges of patients with HoFH. METHODS AND RESULTS: We analysed the data from 3 recent international studies comprising a total of 167 HoFH patients. The age of the patients ranged from 1 to 75 years, and a large proportion of the patients, both treated and untreated, exhibited LDL-C levels well below the recommended clinical diagnostic threshold for HoFH. LDL-C levels ranged from 4.4 mmol/L to 27.2 mmol/L (170-1052 mg/dL) for untreated patients, and from 2.6 mmol/L to 20.3 mmol/L (101-785 mg/dL) for treated patients. When patients were stratified according to LDLR functionality, a similarly wide range of age and LDL-C values was observed regardless of LDLR mutation status. CONCLUSION: These results demonstrate that HoFH is not restricted to very young patients or those with extremely high LDL-C levels.
Authors: Maria Mytilinaiou; Ioannis Kyrou; Mike Khan; Dimitris K Grammatopoulos; Harpal S Randeva Journal: Front Pharmacol Date: 2018-07-12 Impact factor: 5.810
Authors: Poulabi Banerjee; Kuo-Chen Chan; Michel Tarabocchia; Asier Benito-Vicente; Ana C Alves; Kepa B Uribe; Mafalda Bourbon; Paul J Skiba; Robert Pordy; Daniel A Gipe; Daniel Gaudet; Cesar Martin Journal: Arterioscler Thromb Vasc Biol Date: 2019-10-03 Impact factor: 8.311
Authors: Mark Trinder; Martine Paquette; Lubomira Cermakova; Matthew R Ban; Robert A Hegele; Alexis Baass; Liam R Brunham Journal: Circ Genom Precis Med Date: 2020-08-13